SFDA and Singapore HSA Sign MoU for Regulatory Cooperation

The Saudi Food and Drug Authority (SFDA) and Singapore’s Health Sciences Authority (HSA) signed a memorandum of understanding (MoU) on September 17, 2026, in Singapore to strengthen regulatory cooperation and knowledge exchange in pharmaceuticals and medical devices. The agreement was signed by Dr. Hisham Aljadhey, CEO of the SFDA, and Dr. Raymond Chua, CEO of the HSA, following a bilateral meeting held on the sidelines of the 30th Annual Meeting of the International Medical Device Regulators Forum (IMDRF) and the Drug Information Association (DIA) Singapore Annual Meeting.

Context and Background

The MoU marks a significant step in the SFDA’s ongoing efforts to enhance its regulatory framework and align with international best practices. The meeting between Dr. Aljadhey and Dr. Chua explored avenues to deepen cooperation in regulating pharmaceuticals and medical devices, with a particular focus on leveraging artificial intelligence (AI) in regulatory functions. Discussions also addressed optimizing medical device regulatory systems and establishing frameworks for the mutual recognition of Good Manufacturing Practices (GMP). This collaboration underscores Saudi Arabia’s commitment to ensuring the safety, quality, and efficacy of health products, both domestically and globally.

Key Details

Under the MoU, the SFDA and HSA will exchange technical regulations, legislation, standards, and operational best practices. The agreement covers pre-market cooperation in product registration, scientific assessments, risk evaluations, laboratory testing, and reference analysis. It also includes provisions for supply chain oversight, inspection mechanisms, product clearance and traceability, and clinical trials. Post-market information exchanges, such as product safety alerts, are also part of the agreement. Additionally, both authorities will collaborate on regulating novel and innovative products, including advanced applications in biotechnology and AI. This comprehensive framework aims to enhance regulatory efficiency and ensure the safety and quality of health products in both jurisdictions.

Implications and Impact

The MoU is expected to have far-reaching implications for the global regulatory landscape. By facilitating the exchange of expertise and information, the SFDA and HSA aim to streamline regulatory processes, reduce redundancies, and accelerate market access for safe and effective health products. This collaboration could serve as a model for other nations seeking to strengthen their regulatory systems. For Saudi Arabia, the partnership aligns with the Kingdom’s broader strategy to position itself as a leader in healthcare innovation and regulation, in line with Vision 2030. It also reinforces the SFDA’s role as a proactive and reliable regulatory authority on the international stage.

Vision 2030 Alignment

This MoU directly supports Saudi Arabia’s Vision 2030 goals of enhancing healthcare quality and fostering international partnerships. By collaborating with a leading regulatory body like Singapore’s HSA, the SFDA is advancing its mission to protect public health and promote innovation. The exchange of knowledge and best practices will contribute to the development of a robust regulatory ecosystem in the Kingdom, attracting investment and fostering local manufacturing. As Saudi Arabia continues to transform its healthcare sector, such international cooperations are vital to ensuring that patients have access to safe, effective, and high-quality medical products. This agreement exemplifies the Kingdom’s commitment to global cooperation and its drive to achieve excellence in health regulation.

20 Questions

Q1. What is the purpose of the MoU signed between the SFDA and Singapore’s HSA?

A1. The MoU aims to strengthen regulatory cooperation and knowledge exchange in pharmaceuticals and medical devices, enhancing product safety and quality through shared expertise and best practices.

Q2. Who signed the MoU on behalf of the SFDA and HSA?

A2. The MoU was signed by Dr. Hisham Aljadhey, CEO of the SFDA, and Dr. Raymond Chua, CEO of Singapore’s HSA.

Q3. When and where was the MoU signed?

A3. The MoU was signed on September 17, 2026, in Singapore, on the sidelines of the 30th Annual Meeting of the International Medical Device Regulators Forum (IMDRF) and the DIA Singapore Annual Meeting.

Q4. What areas of cooperation does the MoU cover?

A4. It covers pre-market cooperation in product registration, scientific assessments, risk evaluations, laboratory testing, supply chain oversight, inspection mechanisms, product clearance, traceability, clinical trials, and post-market information exchanges.

Q5. How does the MoU address artificial intelligence in regulatory functions?

A5. The MoU includes collaboration on exchanging information and best practices for regulating novel and innovative products, including advanced applications in biotechnology and artificial intelligence.

Q6. What is the significance of mutual recognition of Good Manufacturing Practices (GMP) in the MoU?

A6. Mutual recognition of GMP frameworks aims to streamline regulatory processes and reduce redundancies, facilitating faster market access for safe and effective health products.

Q7. How will the MoU enhance regulatory efficiency?

A7. By exchanging technical regulations, legislation, standards, and operational best practices, the MoU will help both authorities optimize their regulatory systems and ensure product safety and quality.

Q8. What are the post-market information exchanges included in the MoU?

A8. Post-market information exchanges include sharing product safety alerts and other relevant information to ensure ongoing product safety and quality.

Q9. How does this MoU benefit Saudi Arabia’s healthcare sector?

A9. It aligns with Vision 2030 by enhancing healthcare quality, fostering international partnerships, and ensuring access to safe, effective, and high-quality medical products.

Q10. What role does the SFDA play in Saudi Arabia’s Vision 2030?

A10. The SFDA supports Vision 2030 by protecting public health, promoting innovation, and advancing the Kingdom’s regulatory framework to attract investment and foster local manufacturing.

Q11. How does the MoU impact global regulatory practices?

A11. The MoU sets a precedent for international collaboration, potentially streamlining global regulatory processes and accelerating market access for health products.

Q12. What are the key benefits of the SFDA-HSA partnership?

A12. Benefits include enhanced regulatory efficiency, improved product safety and quality, and accelerated access to innovative health products in both jurisdictions.

Q13. How will the exchange of expertise be facilitated under the MoU?

A13. The MoU facilitates the exchange of technical regulations, legislation, standards, and operational best practices through regular communication and collaborative activities.

Q14. What is the role of clinical trials in the MoU?

A14. The MoU includes cooperation on clinical trials, ensuring that they are conducted in compliance with high standards and that results are shared for regulatory purposes.

Q15. How does the MoU address product traceability?

A15. The MoU includes provisions for product clearance and traceability, ensuring that products can be tracked throughout the supply chain to prevent counterfeit or substandard products.

Q16. What are the implications for medical device regulation?

A16. The MoU aims to optimize medical device regulatory systems through shared expertise and mutual recognition of GMP, enhancing safety and efficiency.

Q17. How does the MoU support innovation in biotechnology?

A17. By collaborating on regulating novel and innovative products, including biotechnology applications, the MoU fosters a regulatory environment that supports innovation.

Q18. What is the expected timeline for implementing the MoU?

A18. The MoU is effective immediately, with both authorities committed to ongoing cooperation and information exchange to achieve its objectives.

Q19. How does this MoU reflect Saudi Arabia’s global engagement?

A19. It demonstrates Saudi Arabia’s proactive approach to international collaboration and its commitment to aligning with global best practices in health regulation.

Q20. What future steps will the SFDA and HSA take under this MoU?

A20. Both authorities will continue to exchange information, share best practices, and collaborate on regulatory initiatives to enhance product safety and quality in their respective jurisdictions.

---